Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study

Rheumatology
H Ralph SchumacherChristopher Lademacher

Abstract

This 5-yr study assessed urate-lowering and clinical efficacy and safety of long-term febuxostat therapy in subjects with gout. The primary efficacy end-point was reduction to and maintenance of serum urate (sUA) levels < 6.0 mg/dl. Subjects who completed a previous 28-day study were entered into an open-label extension study and initially received febuxostat 80 mg daily. Between Weeks 4 and 24, dosing could be adjusted to febuxostat 40 or 120 mg. All subjects received gout flare prophylaxis during the first 4 weeks. Gout flares were recorded and treated throughout the study, and sUA, baseline tophi and safety were monitored. Among 116 subjects initially enrolled, dose adjustments were made for 44 (38%) subjects. As a result, 8 subjects received febuxostat 40 mg, 79 received 80 mg, and 29 received 120 mg daily maintenance dose. At 5 yrs, 93% (54/58) of the remaining subjects had sUA < 6.0 mg/dl. Fifty-eight subjects (50%) discontinued prematurely; 38 did so in the first year. Thirteen subjects withdrew due to an adverse event. Sustained reduction of sUA was associated with nearly complete elimination of gout flares. In 26 subjects with a tophus at baseline, resolution was achieved in 69% (18/26) by last visit on study drug at a...Continue Reading

Associated Clinical Trials

References

Dec 1, 1991·Arthritis and Rheumatism·G M McCarthyR L Wortmann
Jul 1, 1974·Annals of the Rheumatic Diseases·I KippenW R Wilcox
Aug 1, 1983·Annals of the Rheumatic Diseases·R W FiddisP D Calvert
May 1, 1995·Arthritis and Rheumatism·M C HochbergM J Klag
Sep 14, 1993·European Journal of Pharmacology·Y OsadaK Komoriya
Jan 1, 1997·Annals of the Rheumatic Diseases·P KlempM C Robertson
May 23, 1998·Advances in Experimental Medicine and Biology·H YamanakaN Kamatani
Sep 5, 2002·Arthritis and Rheumatism·Fernando Perez-RuizAna Ruibal
Oct 24, 2003·The New England Journal of Medicine·Robert A Terkeltaub
Dec 2, 2004·Nucleosides, Nucleotides & Nucleic Acids·S HoshideT Hosoya
Dec 13, 2005·The New England Journal of Medicine·Michael A BeckerNancy Joseph-Ridge
Apr 8, 2006·Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases·Chaitanya A SarawateAlan W Bakst
May 19, 2006·Annals of the Rheumatic Diseases·W ZhangUNKNOWN EULAR Standing Committee for International Clinical Studies Including Therapeutics
Jul 14, 2006·Mayo Clinic Proceedings·Chaitanya A SarawateAlan W Bakst
May 29, 2007·Arthritis and Rheumatism·Jasvinder A SinghSteven M Asch

❮ Previous
Next ❯

Citations

Mar 1, 2012·Zeitschrift für Rheumatologie·B Pazár Maldonado, A So
Mar 31, 2010·Nature Biotechnology·Christian KemmerMartin Fussenegger
Dec 27, 2011·QJM : Monthly Journal of the Association of Physicians·E Suresh, P Das
Oct 8, 2009·Rheumatology·Tom G Rider, Kelsey M Jordan
Jul 15, 2011·Acta Crystallographica. Section E, Structure Reports Online·Qi-Ying JiangXiu-Rong Hu
Aug 6, 2011·International Journal of Rheumatic Diseases·Muhammad K Nisar, K Baburaj
Apr 1, 2009·Therapeutic Advances in Musculoskeletal Disease·Lan X Chen, H Ralph Schumacher
Aug 8, 2012·Therapeutic Advances in Musculoskeletal Disease·Ignacio Garcia-ValladaresLuis R Espinoza
Jan 24, 2013·Therapeutic Advances in Chronic Disease·Christopher M Burns, Robert L Wortmann
Mar 23, 2012·BMC Geriatrics·Robert L JacksonPatricia A MacDonald
Feb 10, 2012·BMC Musculoskeletal Disorders·Alvin F WellsRobert L Jackson
Aug 12, 2009·Arthritis Research & Therapy·Robert Terkeltaub
Apr 8, 2010·Arthritis Research & Therapy·Michael A BeckerChristopher Lademacher
Oct 21, 2010·Arthritis Research & Therapy·Jasvinder A Singh
Feb 20, 2010·Clinical Interventions in Aging·Mattheus K Reinders, Tim L Th A Jansen
Jan 1, 2010·International Journal of Nephrology and Renovascular Disease·Lada Beara-LasicDavid S Goldfarb
Feb 2, 2012·The Physician and Sportsmedicine·Max HamburgerN Lawrence Edwards
Feb 9, 2013·Postgraduate Medicine·Andrew WheltonLhanoo Gunawardhana
Nov 5, 2015·Journal of Medical Economics·Lee J SmolenAki Shiozawa
Apr 2, 2014·Expert Opinion on Drug Metabolism & Toxicology·Harmanjot K GrewalLuis R Espinoza
Nov 6, 2010·Current Medical Research and Opinion·Richard A BrookN Lawrence Edwards
Feb 9, 2016·Journal of Medical Economics·F Perez-RuizD Carcedo
May 27, 2010·Pharmacotherapy·Bryan L LoveK Matthew Snider
Mar 5, 2016·Expert Review of Clinical Pharmacology·Sandra P ChinchillaFernando Perez-Ruiz
Jan 6, 2015·Expert Opinion on Pharmacotherapy·Mary Barna Bridgeman, Benjamin Chavez
Oct 3, 2014·International Journal of Rheumatology·Anne-Kathrin TauscheUte Koch
Aug 26, 2016·Postgraduate Medicine·Gary Ruoff, N Lawrence Edwards
Mar 13, 2018·The New England Journal of Medicine·William B WhiteUNKNOWN CARES Investigators
Mar 9, 2018·Current Rheumatology Reports·Theodore R Fields, Adena Batterman
Mar 9, 2018·Current Rheumatology Reports·David Bursill, Nicola Dalbeth
Oct 5, 2017·Arthritis & Rheumatology·Nicola DalbethLhanoo Gunawardhana
Nov 16, 2012·The Cochrane Database of Systematic Reviews·Jean H TayarMaria E Suarez-Almazor
Jul 20, 2018·Expert Opinion on Pharmacotherapy·Philip C Robinson, Nicola Dalbeth
May 17, 2011·The Journal of Rheumatology·David S GoldfarbLhanoo Gunawardhana
Feb 19, 2011·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Charnelda L Gray, Nafesa E Walters-Smith
Jan 30, 2010·Current Opinion in Rheumatology·John S Sundy
Jan 5, 2010·Nature Reviews. Rheumatology·Robert Terkeltaub
Feb 19, 2010·The Nurse Practitioner·Jennifer M Belavic

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.